Crinetics Pharmaceuticals, Inc.
CRNX
Clasificación en acciones
#2240
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Precio por acción
$84.95
Última sincronización: 2026-09-01
Capitalización bursátil
$9.00B
Cambio (1 día)
0.00%
Cambio (1 año)
100.12%
País
US
Comercio Crinetics Pharmaceuticals, Inc. (CRNX)
Categoría
Healthcare
EPS de Crinetics Pharmaceuticals, Inc. (CRNX)
EPS a fecha de June 2026 TTM: $-5.05
Según los últimos informes financieros y el precio de las acciones de Crinetics Pharmaceuticals, Inc., el EPS actual de la empresa (TTM) es $-5.05. Al final del año 2023, la empresa tenía un EPS de $-3.69 un aumento con respecto a al EPS de 2022, que fue de $-3.15.
Historial de EPS de Crinetics Pharmaceuticals, Inc. desde 2016 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-5.05 | 36.86% |
| 2024 | $-3.69 | 0.00% |
| 2023 | $-3.69 | 17.14% |
| 2022 | $-3.15 | 12.50% |
| 2021 | $-2.80 | 15.70% |
| 2020 | $-2.42 | 18.05% |
| 2019 | $-2.05 | -8.07% |
| 2018 | $-2.23 | 237.88% |
| 2017 | $-0.66 | 53.49% |
| 2016 | $-0.43 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -442.97% |
US
|
|
| $-7.98 | 58.02% |
US
|
|
| $-5.29 | 4.75% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -649.31% |
NL
|
